Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Meropenem

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44380   clinical trials with a EudraCT protocol, of which   7392   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    Query did not match any clinical trials.
    These are paediatric studies completed by 26 January 2007, in respect of products authorised in the Community (Article 45 of the Paediatric Regulation (EC) No 1901/2006).
    Note: Advanced search filters for country, trial phase, gender, rare disease, IMP with orphan designation in the indication and age ranges of in-utero, adult or elderly do not apply to these records.
    Study title: Odio CM, Puig JR, Feris JM, Khan WN, Rodriguez WJ, McCracken GH Jr, Bradley JS. Prospective, randomized, investigator-blinded study of the efficacy and safety of meropenem vs. cefotaxime therapy in bacterial meningitis in children. Meropenem Meningitis Study Group. Pediatr Infect Dis J. 1999 Jul;18(7):581-90.Odio CM, Puig JR, Feris JM, Khan WN, Rodriguez WJ, McCracken GH Jr, Bradley JS. Prospective, randomized, investigator-blinded study of the efficacy and safety of meropenem vs. cefotaxime therapy in bacterial meningitis in children. Meropenem Meningitis Study Group. Pediatr Infect Dis J. 1999 Jul;18(7):581-90.
    Active substance: CEFOTAXIME
    Study summary document link (including results):
    View full study record
    Document reference: 23496
    Study title: Prospective randomized, investigator-blinded study of the efficacy and safety of meropenem Vs cefotaxime therapy in bacterial meningitis in children, Capla M.Odio et al., Pediatr Infect Dis J., 1999;18:581-90Prospective randomized, investigator-blinded study of the efficacy and safety of meropenem Vs cefotaxime therapy in bacterial meningitis in children, Capla M.Odio et al., Pediatr Infect Dis J., 1999;18:581-90
    Active substance: CEFOTAXIME
    Study summary document link (including results):
    View full study record
    Document reference: 23500
    Study title: Randomized comparison of meropenem with cefotaxime for treatment of bacterial meningitis, Keith P.Klugman, Ron Dagan, Meropenen Meningitis Study Group, Antimicrobial Agents and Chemotherapy, May 1995, p. 1140-1146.Randomized comparison of meropenem with cefotaxime for treatment of bacterial meningitis, Keith P.Klugman, Ron Dagan, Meropenen Meningitis Study Group, Antimicrobial Agents and Chemotherapy, May 1995, p. 1140-1146.
    Active substance: CEFOTAXIME
    Study summary document link (including results):
    View full study record
    Document reference: 23501
    Study title: Randomized comparison of meropenem with cefotaxime for treatment of bacterial meningitis, Keith P.Klugman, Ron Dagan, Meropenen Meningitis Study Group, Antimicrobial Agents and Chemotherapy, May 1995, p. 1140-1146.Randomized comparison of meropenem with cefotaxime for treatment of bacterial meningitis, Keith P.Klugman, Ron Dagan, Meropenen Meningitis Study Group, Antimicrobial Agents and Chemotherapy, May 1995, p. 1140-1146.
    Active substance: CEFOTAXIME
    Study summary document link (including results):
    View full study record
    Document reference: 23502
    Study title: A Multicentre Open Randomised Parallel-Group Trial of Meropenem versus Ceftoxamine plus Metronidazole in the Treatment of Abdominal Infections
    Active substance: MEROPENEM TRIHYDRATE
    Study summary document link (including results): 3591IL0027.xls
    View full study record
    Document reference: 31623
    Study title: A Single-Blind Randomised Comparative Study of MERREM (Meropenem) Versus Cefotaxime in the Treatment of Acute Bacterial Meningitis in Hospitalised Infants and Children.
    Active substance: MEROPENEM TRIHYDRATE
    Study summary document link (including results): 3591IL0065.xls
    View full study record
    Document reference: 31621
    Study title: Efficacy and tolerability of Meropenem 20 mg/kg tid in infants (3-12 months old) vs meropenem tid in children (1-14 years old) for the initial treatment of severe infections in hospitalised children.
    Active substance: MEROPENEM TRIHYDRATE
    Study summary document link (including results): 3591IL9003.xls
    View full study record
    Document reference: 31622
    Study title: Meropenem versus Ceftazidime plus Amikacin as Empirical Therapy for Fever in Cancer Patients with Granulocytopenia; A Prospective, Randomised, Multicentre Study.
    Active substance: MEROPENEM TRIHYDRATE
    Study summary document link (including results):
    View full study record
    Document reference: 31620
    Study title: Support for recruitment to Turkish study comparing Merrem with Ceftazidime + Amikacin in the empirical treatment of febrile infective episodes in neutropenic padiatric patients in Latin America.
    Active substance: MEROPENEM TRIHYDRATE
    Study summary document link (including results): 3591IL9006.xls
    View full study record
    Document reference: 31624
    Study title:
    Active substance: MEROPENEM TRIHYDRATE
    Study summary document link (including results): 3591IL0020 21 22.xls
    View full study record
    Document reference: 31625
    Study title:
    Active substance: MEROPENEM TRIHYDRATE
    Study summary document link (including results): 3591IL0045.xls
    View full study record
    Document reference: 45255
    Study title:
    Active substance: MEROPENEM TRIHYDRATE
    Study summary document link (including results): 3591US0001.xls
    View full study record
    Document reference: 45256
    Study title:
    Active substance: MEROPENEM TRIHYDRATE
    Study summary document link (including results): 3591IL0062.xls
    View full study record
    Document reference: 45257
    Study title:
    Active substance: MEROPENEM TRIHYDRATE
    Study summary document link (including results): 3591US0013.xls
    View full study record
    Document reference: 45258
    Study title:
    Active substance: MEROPENEM TRIHYDRATE
    Study summary document link (including results): 1946600600.xls
    View full study record
    Document reference: 45259
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue Feb 10 15:43:44 CET 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA